Oxygen Biotherapeutics Announces Closing of Its Previously Announced Private Placement of Unregistered Convertible Notes and Warrants
01. Juli 2011 16:05 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., July 1, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that it closed its previously announced private placement of...
Oxygen Biotherapeutics Announces $4.6 Million Private Placement of Unregistered Convertible Note and Warrants
22. Juni 2011 12:10 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., June 22, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that it has entered into an agreement for the issuance and...
Oxygen Biotherapeutics Receives Approval to Expand Phase IIb Trials With Oxycyte(R) PFC for Traumatic Brain Injury Into India
07. Juni 2011 02:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., June 7, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received approval by the Drug Controller General of...
Oxygen Biotherapeutics' Chairman and CEO Chris Stern Announces Retirement of President and COO Richard Kiral
31. März 2011 17:30 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 31, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced the Board of Directors accepted the resignation of President...
Oxygen Biotherapeutics Reports Financial Results for Third Quarter FY2011
21. März 2011 18:03 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 21, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich...
Oxygen Biotherapeutics Announces Third Quarter FY2011 Financial Results Conference Call and Webcast
14. März 2011 18:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 14, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the Company plans to report third quarter fiscal year...
Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Mexican Sales and Distribution Company
10. März 2011 02:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has entered into an agreement with independently owned and...
Oxygen Biotherapeutics Receives U.S. Army Grant for Studies of Oxycyte(R), a Novel Traumatic Brain Injury Therapeutic for Combat Casualties
02. März 2011 02:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 2, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received a $2.075 million, two-year grant from the U.S....
Oxygen Biotherapeutics and Hackensack University Medical Center Sign Research Contract Funded by the U.S. Department of Defense to Study Wound Healing Properties of Wundecyte(TM) Gel
28. Januar 2011 00:30 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SWX:OXBT) today announced it has signed a research contract with Hackensack University Medical Center (HUMC)...
Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Swiss Sales and Distribution Company
12. Januar 2011 11:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C. and ZURICH, Switzerland, Jan. 12, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced it has entered into an agreement with the newly formed,...